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Poster Session II S289NRM incidence significantly decreased over the three periods (30%,
24%, and 22%, p\0.001) mainly due to a reduced risk of death as-
sociated with organ failure (14%, 9%, and 7%, p 5 0.005) and
GVHD (7%, 3%, and 3%, p\ 0.001), which led to a significantly
improved OS (58%, 59%, and 64%, p 5 0.008). In older patients
who received allo-HCT from a related donor, NRM significantly
improved in 2005-2008 compared to 2001-2004 (29% vs 18%, p
\0.001) due to a reduced risk of death associated with organ failure
(11% vs 6%, p5 0.007) andGVHD (6% vs 3%, p5 0.11). However,
due to the increase in the incidence of relapse in 2005-2008, this
decreased NRM did not lead to an improvement of OS (51% vs
55%, p 5 0.21). In older patients who received allo-HCT from an
alternative donor, NRM and OS significantly improved in 2005-
2008 compared to 2001-2004 (NRM, 43% vs 31%; OS, 40% vs
51%, p\ 0.001). The reduction in NRM was mainly due to a de-
crease in death associated with infection (17% vs 11%, p 5 0.007)
and GVHD (7% vs 4%, p 5 0.152).
Conclusions: NRM and OS have recently improved, especially for
allo-HCT from unrelated BM or CB donors. These advances
seemed to be due to a reduced risk of death associated with
GVHD in both younger and older patients.374
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Intro: For unrelated donor allografts, higher cell doses improve out-
comes. Increasingly, older patient age is prompting consideration of
older sibling donors. On average, older donors mobilize PBSC less
well.We hypothesized that outcomes would be worse after older sib-
ling PBSC allografts as older age adversely impacts PBSC yields.
Methods:We reviewed transplant outcomes fromHLAmatched or
single antigen/allele mismatched siblings harvested between January
2001 and April 2008. Donors underwent uniform PBSC mobiliza-
tion of G-CSF at 10 mcg/kg/day and apheresis on day 5. We evalu-
ated the influence donor and recipient age as continuous variables.
We also explore the allograft dose by CD34 dose infused above
the median and the peripheral blood (PB) CD34 on day 5 pre-apher-
esis (a biologic measure of mobilization capacity of the donor). All
diseases and conditioning regimens were included. The majority of
patients underwent regimens incorporating campath.
Results: Of the 195 sibling donors who underwent mobilization,
182 pts (93%) were infused with PBSCs from one mobilization at-
tempt. The median donor age was 52 years (range 16-70) and
16.9% were 60 years or older. Median recipient age was 53.2 years.
The median CD34 infused was 5.4 x10(6)/kg (range 0.34 to 13.2).
The risk of acute II-IV GVHD did not correlate with older donor
age (HR 5 1.01, P0.49), recipient age (HR 5 1.04, 95%CI, 0.99-
1.09; P 5 0.06), CD34 infused above the median (HR 5 1.19, P 5
0.12), or higher pre-apheresis PB CD34 (HR 5 1.01, P 5 0.82).
However, only 22 recipients developed aGVHD. Donor age was
not associated with relapse free survival (RFS) (HR 5 1.06, P 5
0.45) or OS (HR 5 1.06, P 5 0.53). Older recipients, however,
had inferior OS (HR 5 1.02, P 5 0.014) but not RFS (HR 5 1.01,
P 5 0.30). OS was not associated with peak PB pre-apheresis
CD34 (P 5 0.73) or CD34 infused (P 5 0.85). In multivariate anal-
ysis of donor age, recipient age, disease status and CD34 infused,
higher CD34 infused did not impact OS. While older recipient
age demonstrated a strong association with poorer OS (P 5 .008),
older donor age showed a borderline associated with improved OS
(PS 5 .049).
Conclusion: After adjusting for recipient age and disease, lower
CD34 infused and older donor age had no detrimental impact on
GVHD, relapse, or OS. Absent data showing a benefit of younger
unrelated donors, we conclude that medically cleared older sibiling
donors should be considered the standard of care when available,
at least up to age 70 years.375
ALEMTUZUMAB VS ATG FOR T-CELL DEPLETION IN SIBLING DONOR RE-
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(RIC HSCT) FOR THE TREATMENT OF ACUTE MYELOID LEUKAEMIA
AND MYELODYSPLASTIC SYNDROME
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We report the results of a retrospective analysis on 83 patients who
underwentHLA-matched sibling donor RICHSCT receiving either
ATG or alemtuzumab. All patients received a uniform protocol of
fludarabine and busulfan. For T-cell depletion/GVHD prophylaxis
48 patients received alemtuzumab(20mg x 5 days IV) followed by
cyclosporin A post-transplant. 35 patients received ATG(Thymo-
globulin, Genzyme)(total 6mg/kg over 3 days IV) followed by meth-
otrexate/cyclosporine A post-transplant.
Diagnoses included myelodysplastic syndrome (MDS)(n 5 34),
acute myeloid leukaemia (AML)(n 5 40) or MDS/MPD(n 5 9).
Median recipient age was 56yrs(range 22-72) in both groups. All pa-
tients received PBSC with median CD34 cell dose of 5.06 x106/kg.
There were no significant differences between groups with regard
to age, disease type, cytogenetic risk, disease stage at transplantation,
or CD34 cell dose. Median follow-up (for survivors) was 743 days
(range 31-1516) for ATG and 2193 days (range: 39-3595) for
alemtuzumab.
Median time to neutrophil (0.5x10^9/L) regeneration was 14 days
in both groups. There were 3 primary graft failures (1 ATG, 2 alem-
tuzumab).Median donor CD3 chimerism to day 100(alemtuzumab v
ATG) was 73% v 65% at D30, 74% v 69.5% at D60 and 67% v 44%
at D100(p5NS). A higher proportion of patients receiving alemtu-
zumab required subsequent DLI therapy (68.8 v 31.4% p 5 0.001).
The main reason for DLI in each group was falling donor chimerism
(61 v 57.1%p5NS). The incidence of de novo cGVHD was higher
in the ATG arm(25.6 v 8.3% p 5 0.06), however this was offset by
subsequent development of cGVHD in the alemtuzumab arm due
to greater DLI administration. Consequently overall rates of chronic
GVHDwere similar between alemtuzumab and ATG arms(41.2% v
40%). The 2-year OS in the ATG v alemtuzumab group was 67.8
+/2 8.5% vs 50.3 +/2 7.4%(p 5 0.38). DFS was 51 +/2 9.4% in
ATG patients, vs 38.3 +/27.1% in alemtuzumab patients. There
was no significant difference in TRMor relapse between the alemtu-
zumab vs ATG group 27+/27.5% v 15+/26.9%, (p 5 0.48), and
47.5+/27.8% vs 43.8 +/2 9.8%.
In summary, our experience indicates that in patients with MDS/
AML having sibling donor RIC HSCT, use of ATG results in com-
parable outcomes when compared with alemtuzumab, with signifi-
cantly lower need for DLI. While the incidence of GvHD is
similar between groups, ATG patients are more likely to develop
de novo GvHD when compared with alemtuzumab patients who
develop delayed GvHD following DLI.376
SILICA-INDUCED IMPAIRMENT OF MACROPHAGE FUNCTION REDUCES
GVHD SEVERITY AND IMPROVES SURVIVAL
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Acute graft versus host disease (GVHD) is a major complication of
bonemarrow transplantation (BMT). The pathogenesis of GVHD is
characterized by a cascade of inflammatory cytokines and effector
molecules that maintain a proinflammatorymilieu capable of contin-
uously activating immune cells leading to tissue injury. Several stud-
ies have demonstrated a role for macrophages in secreting these
proinflammatory mediators during GVHD progression. Silica
decreases the phagocytic capacity of macrophages and alters their ca-
pacity to activate T cells by switching from a Th1 to a Th2 response.
Therefore, we investigate whether altering macrophage function by
in vivo administration of silica would result in alleviation of GVHD
symptoms and improved survival. Mice were lethally irradiated and
transplanted with with 5x106 allogeneic T-cell depleted bone mar-
row cells (TCD-BM) and 7.5x105 allogeneic conventional T cells
(Tcon) to induce GVHD. A significant increase in median survival
